JP2016537027A - ジスルフィド基を有するポリヌクレオチド構築物 - Google Patents

ジスルフィド基を有するポリヌクレオチド構築物 Download PDF

Info

Publication number
JP2016537027A
JP2016537027A JP2016553242A JP2016553242A JP2016537027A JP 2016537027 A JP2016537027 A JP 2016537027A JP 2016553242 A JP2016553242 A JP 2016553242A JP 2016553242 A JP2016553242 A JP 2016553242A JP 2016537027 A JP2016537027 A JP 2016537027A
Authority
JP
Japan
Prior art keywords
optionally substituted
alkyl
group
aryl
polynucleotide construct
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016553242A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016537027A5 (cg-RX-API-DMAC7.html
Inventor
ブラッドショー，コート，ダブリュ．
エルテプ，ラクスマン
カバキビ，アイマン
ラム，ソン
リウ，ビン
リウ，ディングオ
ミード，ブライアン，アール．
サカムリ，スクマー
Original Assignee
ソルスティス バイオロジクス，リミティッド
ソルスティス バイオロジクス，リミティッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ソルスティス バイオロジクス，リミティッド, ソルスティス バイオロジクス，リミティッド filed Critical ソルスティス バイオロジクス，リミティッド
Publication of JP2016537027A publication Critical patent/JP2016537027A/ja
Publication of JP2016537027A5 publication Critical patent/JP2016537027A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/311—Phosphotriesters
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2016553242A 2013-11-06 2014-11-06 ジスルフィド基を有するポリヌクレオチド構築物 Pending JP2016537027A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201361900685P 2013-11-06 2013-11-06
US61/900,685 2013-11-06
US201461975686P 2014-04-04 2014-04-04
US61/975,686 2014-04-04
US201462008906P 2014-06-06 2014-06-06
US62/008,906 2014-06-06
PCT/US2014/064401 WO2015069932A1 (en) 2013-11-06 2014-11-06 Polynucleotide constructs having disulfide groups

Publications (2)

Publication Number Publication Date
JP2016537027A true JP2016537027A (ja) 2016-12-01
JP2016537027A5 JP2016537027A5 (cg-RX-API-DMAC7.html) 2017-12-14

Family

ID=53042090

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016553242A Pending JP2016537027A (ja) 2013-11-06 2014-11-06 ジスルフィド基を有するポリヌクレオチド構築物

Country Status (7)

Country Link
US (1) US20160257961A1 (cg-RX-API-DMAC7.html)
EP (1) EP3066105A4 (cg-RX-API-DMAC7.html)
JP (1) JP2016537027A (cg-RX-API-DMAC7.html)
CN (1) CN106061981A (cg-RX-API-DMAC7.html)
AU (1) AU2014346658A1 (cg-RX-API-DMAC7.html)
CA (1) CA2929651A1 (cg-RX-API-DMAC7.html)
WO (1) WO2015069932A1 (cg-RX-API-DMAC7.html)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020512843A (ja) * 2017-04-14 2020-04-30 トルニネ， インコーポレイテッド 免疫調節ポリヌクレオチド、その抗体コンジュゲート、及びそれらの使用方法
JP2024501857A (ja) * 2020-12-31 2024-01-16 アルナイラム ファーマシューティカルズ， インコーポレイテッド 環状ジスルフィド修飾リン酸ベースのオリゴヌクレオチドプロドラッグ
WO2025160446A1 (en) * 2024-01-25 2025-07-31 Ai Proteins, Inc. Methods and systems for characterizing structural features of a protein

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160303242A1 (en) 2013-12-09 2016-10-20 Durect Corporation Pharmaceutically Active Agent Complexes, Polymer Complexes, and Compositions and Methods Involving the Same
JP2017522046A (ja) * 2014-06-06 2017-08-10 ソルスティス バイオロジクス，リミティッド 生物可逆的および生物不可逆的基を有するポリヌクレオチド構築物
WO2016146143A1 (en) 2015-03-16 2016-09-22 Amal Therapeutics Sa Cell penetrating peptides and complexes comprising the same
CN105175546A (zh) * 2015-05-27 2015-12-23 连祺周 人血管内皮生长因子与表皮生长因子样结构域7的融合蛋白
JPWO2016208773A1 (ja) * 2015-06-26 2018-04-12 協和発酵キリン株式会社 オリゴヌクレオチド誘導体
CN105037739B (zh) * 2015-07-28 2017-10-27 四川大学 具有精氨酸穿膜作用的还原敏感型聚合物及其制备方法与应用
TWI639614B (zh) * 2015-11-06 2018-11-01 美商齊亞雋科學公司 核苷酸類似物
WO2017100461A1 (en) * 2015-12-08 2017-06-15 Solstice Biologics, Ltd. Polynucleotide constructs having an auxiliary moiety non-bioreversibly linked to an internucleoside phosphate or phosphorothioate
HUE066998T2 (hu) 2016-03-16 2024-09-28 Amal Therapeutics Sa Egy immunellenõrzõpont-modulátor és egy sejtpenetráló peptidet, kargót és TLR peptidagonistát tartalmazó komplex kombinációja gyógyászatban történõ alkalmazásra
ES2952757T3 (es) * 2016-06-30 2023-11-03 Kyowa Kirin Co Ltd Complejo de ácidos nucleicos
AU2017311510B2 (en) 2016-08-10 2021-11-18 Cancer Targeted Technology Llc Chelated PSMA inhibitors
CA3033867A1 (en) 2016-08-17 2018-02-22 Solstice Biologics, Ltd. Polynucleotide constructs
CA3032165C (en) * 2016-08-23 2023-05-16 Dicerna Pharmaceuticals, Inc. Compositions comprising reversibly modified oligonucleotides and uses thereof
WO2018055060A1 (en) 2016-09-21 2018-03-29 Amal Therapeutics Sa Fusion comprising a cell penetrating peptide, a multi epitope and a tlr peptide agonist for treatment of cancer
JP7167021B2 (ja) * 2016-11-23 2022-11-08 キャンサー ターゲテッド テクノロジー エルエルシー アルブミン結合ｐｓｍａ阻害剤
US11597744B2 (en) 2017-06-30 2023-03-07 Sirius Therapeutics, Inc. Chiral phosphoramidite auxiliaries and methods of their use
WO2019161105A1 (en) 2018-02-14 2019-08-22 Deep Genomics Incorporated Oligonucleotide therapy for wilson disease
US20220096649A1 (en) * 2018-10-17 2022-03-31 Tallac Therapeutics, Inc. Immunomodulating polynucleotide conjugates and methods of use
CN109384715B (zh) * 2018-11-19 2021-09-03 复旦大学附属肿瘤医院 前列腺特异性膜抗原的小分子抑制剂的制备方法
JP2023501020A (ja) * 2018-12-28 2023-01-18 サーナオミクス インコーポレイテッド 治療用分子の標的化送達
CN119607006A (zh) 2019-12-09 2025-03-14 艾姆皮瑞克公司 用于治疗血管生成素样4(angptl4)相关疾病的寡核苷酸
EP4110830A4 (en) 2020-02-28 2024-09-11 Tallac Therapeutics, Inc. TRANSGLUTAMINASE-MEDIATED CONJUGATION
CN112402620A (zh) * 2020-12-07 2021-02-26 南开大学 肿瘤微环境还原响应性的纳米药物及其制备方法
CN112679583B (zh) * 2021-01-07 2022-02-22 杭州医学院 一种靶向癌蛋白boris的特异性多肽及其应用和基因
WO2022161452A1 (zh) * 2021-01-28 2022-08-04 南京桦冠生物技术有限公司 缀合物及其用途
CN112898206A (zh) * 2021-02-05 2021-06-04 河北凡博医药科技有限公司 一种5,6-二甲基苯并咪唑的制备方法
CN113024854B (zh) * 2021-03-24 2022-06-03 西南石油大学 一种结构可控且规整的凝胶材料的制备方法
CN119213005A (zh) 2022-03-16 2024-12-27 艾姆皮瑞克公司 用于提高siRNA生物利用度的GALNAC组合物
CN120112641A (zh) * 2022-10-31 2025-06-06 大睿生物医药科技(上海)有限公司 向细胞内递送siRNA的前药
CN115925586A (zh) * 2022-11-01 2023-04-07 青岛蓝谷多肽生物医药科技有限公司 一种靶向psma的母体及其衍生物的制备方法
CN116715624B (zh) * 2023-06-14 2025-11-28 信阳师范学院 一种n-烷基化吡啶硫酮类化合物的合成方法

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05505941A (ja) * 1990-03-29 1993-09-02 ギリード　サイエンシズ　インコーポレーテッド オリゴヌクレオチド―輸送剤ジスルフィド結合体
US20030105026A1 (en) * 2001-02-08 2003-06-05 Kozhemyakin Leonid A. Compounds comprising disulfide-containing peptides and nitrogenous bases, and medical uses thereof
JP2004536027A (ja) * 2000-12-01 2004-12-02 ジョーンズ・ホプキンス・ユニーバーシティー グリコシル化／ガラクトシル化ペプチドの接合体、二官能性リンカー、およびヌクレオチドのモノマー／ポリマー、および関連する組成物および使用方法
JP2004537535A (ja) * 2001-06-21 2004-12-16 ダイナバックス テクノロジーズ コーポレイション キメラ免疫調節化合物とその使用方法
US20070123450A1 (en) * 1998-11-23 2007-05-31 Novelos Therapeutics, Inc. Methods for production of the oxidized glutathione composite with CIS-diamminedichloroplatinum and pharmaceutical compositions based thereof regulating metabolism, proliferation, differentiation and apoptotic mechanisms for normal and transformed cells
JP2010521657A (ja) * 2007-03-05 2010-06-24 ニューサウス イノベイションズ ピーティーワイ リミテッド 有糸分裂阻害剤に対する腫瘍細胞の感受性を検出してモジュレートするための方法
US20110312507A1 (en) * 2005-07-15 2011-12-22 President And Fellows Of Harvard College Reaction discovery system
WO2013012758A1 (en) * 2011-07-19 2013-01-24 Ontorii, Inc. Methods for the synthesis of functionalized nucleic acids
WO2013126034A1 (en) * 2012-02-22 2013-08-29 Chemgenes Corporation Synthesis of high purity dmt-c3-disulfide phosphoramidite

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6610841B1 (en) * 1997-12-18 2003-08-26 Gilead Sciences, Inc. Nucleotide-based prodrugs
US7785610B2 (en) * 2001-06-21 2010-08-31 Dynavax Technologies Corporation Chimeric immunomodulatory compounds and methods of using the same—III
EP2438079A4 (en) * 2009-06-01 2013-05-22 Univ California NUCLEIC ACID DELIVERY COMPOSITIONS AND METHOD OF USE THEREOF
CN104781271B (zh) * 2012-08-20 2018-07-06 加利福尼亚大学董事会 具有生物可逆的基团的多核苷酸

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05505941A (ja) * 1990-03-29 1993-09-02 ギリード　サイエンシズ　インコーポレーテッド オリゴヌクレオチド―輸送剤ジスルフィド結合体
US20070123450A1 (en) * 1998-11-23 2007-05-31 Novelos Therapeutics, Inc. Methods for production of the oxidized glutathione composite with CIS-diamminedichloroplatinum and pharmaceutical compositions based thereof regulating metabolism, proliferation, differentiation and apoptotic mechanisms for normal and transformed cells
JP2004536027A (ja) * 2000-12-01 2004-12-02 ジョーンズ・ホプキンス・ユニーバーシティー グリコシル化／ガラクトシル化ペプチドの接合体、二官能性リンカー、およびヌクレオチドのモノマー／ポリマー、および関連する組成物および使用方法
US20030105026A1 (en) * 2001-02-08 2003-06-05 Kozhemyakin Leonid A. Compounds comprising disulfide-containing peptides and nitrogenous bases, and medical uses thereof
JP2004537535A (ja) * 2001-06-21 2004-12-16 ダイナバックス テクノロジーズ コーポレイション キメラ免疫調節化合物とその使用方法
US20110312507A1 (en) * 2005-07-15 2011-12-22 President And Fellows Of Harvard College Reaction discovery system
JP2010521657A (ja) * 2007-03-05 2010-06-24 ニューサウス イノベイションズ ピーティーワイ リミテッド 有糸分裂阻害剤に対する腫瘍細胞の感受性を検出してモジュレートするための方法
WO2013012758A1 (en) * 2011-07-19 2013-01-24 Ontorii, Inc. Methods for the synthesis of functionalized nucleic acids
WO2013126034A1 (en) * 2012-02-22 2013-08-29 Chemgenes Corporation Synthesis of high purity dmt-c3-disulfide phosphoramidite

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BIOORG. MED. CHEM. LETT., 2013, 23(7), PP.2098-2100, EPUB 2013 FEB 8, JPN6018041868, ISSN: 0004083012 *
NUCLEIC ACIDS RES., 1987, 15(13), PP.5305-5321, JPN6018041867, ISSN: 0004083011 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020512843A (ja) * 2017-04-14 2020-04-30 トルニネ， インコーポレイテッド 免疫調節ポリヌクレオチド、その抗体コンジュゲート、及びそれらの使用方法
JP2024167198A (ja) * 2017-04-14 2024-12-03 タラック セラピューティクス，インコーポレイテッド 免疫調節ポリヌクレオチド、その抗体コンジュゲート、及びそれらの使用方法
JP2024501857A (ja) * 2020-12-31 2024-01-16 アルナイラム ファーマシューティカルズ， インコーポレイテッド 環状ジスルフィド修飾リン酸ベースのオリゴヌクレオチドプロドラッグ
WO2025160446A1 (en) * 2024-01-25 2025-07-31 Ai Proteins, Inc. Methods and systems for characterizing structural features of a protein

Also Published As

Publication number Publication date
AU2014346658A1 (en) 2016-06-02
US20160257961A1 (en) 2016-09-08
CA2929651A1 (en) 2015-05-14
EP3066105A1 (en) 2016-09-14
CN106061981A (zh) 2016-10-26
EP3066105A4 (en) 2017-10-11
WO2015069932A1 (en) 2015-05-14

Similar Documents

Publication Publication Date Title
JP2016537027A (ja) ジスルフィド基を有するポリヌクレオチド構築物
US20200392498A1 (en) Polynucleotide constructs having bioreversible and non-bioreversible groups
US20180303864A1 (en) Polynucleotides having bioreversible groups
US20240247025A1 (en) Polynucleotide constructs
US20240175019A1 (en) Skeletal Muscle Delivery Platforms and Methods of Use
US20190194655A1 (en) Polynucleotide constructs having an auxiliary moiety non-bioreversibly linked to an internucleoside phosphate or phosphorothioate
CN101506368A (zh) 通过可逆的磷酸三酯电荷中和保护基转导运输核酸
AU2022349576A1 (en) Multivalent ligand clusters with diamine scaffold for targeted delivery of therapeutic agents
CA3120580A1 (en) Rnai agents for inhibiting expression of hif-2 alpha (epas1), compositions thereof, and methods of use

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160509

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20161102

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20161102

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171106

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20171106

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181030

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190118

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190730